期刊
TRENDS IN BIOTECHNOLOGY
卷 25, 期 4, 页码 145-152出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibtech.2007.02.005
关键词
-
资金
- NCI NIH HHS [CA95026, CA75123, CA79663] Funding Source: Medline
- NHLBI NIH HHS [HL-69256] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R01CA095026, R21CA079663, R01CA075123] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069256] Funding Source: NIH RePORTER
Nanotechnology has considerable promise for the detection, staging and treatment of cancer. Here, we outline one such promising application: the use of nanostructures with surface-bound ligands for the targeted delivery and ablation of colorectal cancer (CRC), the third most common malignancy and the second most common cause of cancer-related mortality in the US. Normal colonic epithelial cells as well as primary CRC and metastatic tumors all express a unique surface-bound guanylyl cyclase C (GCC), which binds the diarrheagenic bacterial heat-stable peptide enterotoxin ST. This makes GCC a potential target for metastatic tumor ablation using ST-bound nanoparticles in combination with thermal ablation with near-infrared or radiofrequency energy absorption. Furthermore, the incorporation of iron or iron oxide into such structures would provide advantages for magnetic resonance imaging (MRI). Although the scenarios outlined in this article are hypothetical, they might stimulate ideas about how other cancers could be attacked using nanotechnology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据